Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Allergy & Immunology
•
Pulmonology
•
Diffuse Parenchymal Lung Disease
•
Primary Immunodeficiency
How often are you performing CT screening in CVID patients to screen for ILD?
Related Questions
Are there certain clinical features that help you choose between benralizumab and mepolizumab for EGPA in clinical practice?
Are there benefits to adding IL5/IL5 receptor blockade in patients with vasculitic manifestations of EGPA?
Do you utilize cytokine panels to guide treatment of patients with EGPA?
Is there any indication for IVIG in immunocompromised patients with only decreased IgM and/or IgA levels?
What factors would encourage you to choose abatacept vs tocilizumab in a patient with RA-ILD with a UIP pattern of pulmonary fibrosis?
Do you seek pathologic confirmation before proceeding with empiric immunosuppressive therapy in symptomatic patients with radiographic NSIP?
How would you approach diagnosis of a patient with recurrent episodes of abdominal pain, severe myalgias, low grade fevers and urticaria?
How would you approach management of a patient with seropositive RA and UIP-ILD, with concern for active lung disease?
Is there any value to IgG subclasses in assessing immune deficiency in a patient with normal IgG levels?
What is the role of inebilizumab in the maintenance treatment of IgG4-related disease?
